Walking the tightrope: Expectations and standards in personal genomics

BioSocieties

Volumn 8, Issue 2, 2013, Pages 181-204

  Groves, Christopher ^a   Tutton, Richard ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

direct to consumer genetic testing; personal genomics; personalised medicine; regulation; sociology of expectations; standardisation

Indexed keywords

EID: 84878595751     PISSN: 17458552     EISSN: 17458560     Source Type: Journal    
DOI: 10.1057/biosoc.2013.1     Document Type: Article

References (62)

1. Adam, B. and Groves, C. (2007) Future Matters: Action, Knowledge, Ethics. Leiden, The Netherlands: Brill.
2. Bakker, S., Van Lente, H. and Meeus, M. (2011) Arenas of expectations for hydrogen technologies. Technological Forecasting and Social Change 78(1): 152-162.
3. Becker, D. (2010) Testimony of David Becker to U.S. house of representatives committee on energy and commerce, 22 July, http://democrats. energycommerce.house.gov/documents/20100722/Becker.Testimony .07.22.2010.pdf, accessed 16 July 2011.
4. Bloss, C.S., Madlensky, L., Schork, N.J. and Topol, E.J. (2011) Genomic information as a behavioral health intervention: Can it work? Personalized Medicine 8(6): 659-667.
5. Borup, M., Brown, N., Konrad, K. and van Lente, H. (2006) The sociology of expectations in science and technology. Technology Analysis & Strategic Management 18(3-4): 285-298. (Pubitemid 44083929)
6. Brown, N. (2005) Shifting tenses: Reconnecting regimes of truth and hope. Configurations 13(3): 331-355.
7. Busch, L. (2011) Standards: Recipes for Reality. Cambridge, MA, London: MIT Press.
8. Carmichael, M. (2010) DNA Dilemma: The Full Interview with the FDA on DTC Genetic Tests, [online], http://www.thedailybeast.com/newsweek/blogs/the-human- condition/2010/08/05/dna-dilemma-the-full-interview- with-the-fda-on-dtc- genetic-tests.html, accessed 12 October 2010.
9. Cornel, M.C. et al (2011) Genetic testing and common disorders: How to assess relevance and possibilities. European Journal of Human 19: S6-S44.
10. Curnutte, M. and Testa, G. (2012) Consuming genomes: Scientific and social innovation in direct-toconsumer genetic testing. New Genetics and Society 31(2): 159-181.
11. de Souza, N. (2012) Genomics: The ENCODE project. Nature Methods 9(11): 1046-1046.
12. Federation of European Academies of Medicine (FEAM). (2012) Direct-to-Consumer Genetic Testing for Health-Related Purposes in the European Union: The View from EASAC and FEAM. Brussels, Belgium: European Academies Science Advisory Council.
13. Feero, W.G., Guttmacher, A.E. and Collins, F.S. (2008) The genome gets personal - almost. JAMA: The Journal of the American Medical Association 299(11): 1351-1352. (Pubitemid 351439081)
14. Fleming, N. (2008) Rival Genetic Tests Leave Buyers Confused, London: Times Newspapers, http://www .timesonline.co.uk/tol/news/science/article4692891. ece, accessed 9 June 2011.
15. Foster,M., Mulvihill, J. and Sharp, R. (2009) Evaluating the utility of personal genomic information. Genetics in Medicine 11(8): 570-574.
16. Fraker, M. and Mazza, A.-M. (2011) Personal Genomics: Establishing the Scientific Foundation for Using Personal Genome Profiles for Risk Assessment, Health Promotion, and Disease Prevention. Washington DC: National Academies Press.
17. Garud, R. and Ahlstrom, D. (1997) Technology assessment: A socio-cognitive perspective. Journal of Engineering and Technology Management 14(1): 25-48. (Pubitemid 127372158)
18. Goetz, T. (2007) 23AndMe will decode your DNA for $1000. Welcome to the age of genomics. Wired, [online], 17 November, http://www.wired.com/ medtech/genetics/magazine/15-12/ff-genomics, accessed 15 July 2011.
19. Gould, A. (2010) Testimony of Ashley C. Gould, General Counsel, 23andMe, Inc. Washington DC, http://democrats.energycommerce.house.gov/documents/ 20100722/Gould.Testimony.07.22.2010.pdf, accessed 20 June 2011.
20. Grosse, S.D., McBride, C.M., Evans, J.P. and Khoury, M.J. (2009) Personal utility and genomic information: Look before you leap. Genetics in Medicine 11(8): 575-576.
21. Groves, C. (2009) Nanotechnology, contingency and finitude. Nanoethics 3(1): 1-16.
22. Hall, W.D., Mathews, R. and Morley, K.I. (2010) Being more realistic about the public health impact of genomic medicine. PLoS Med 7(10): e1000347.
23. Hsu, A.R., Avey, L., Mountain, J.L. and Wojcicki, A. (2009) A pragmatic consideration of ethical issues relating to personal genomics. American Journal of Bioethics 9(6-7): 1-2.
24. Hudson, K., Javitt, G., Burke, W. and Byers, P. (2007) ASHG statement on direct-to-consumer genetic testing in the United States. American Journal of Human Genetics 81(3): 635-637.
25. International Standards Organisation (ISO). (2007) ISO/TC 229 Business Plan. Geneva, Switzerland: ISO.
26. Janssens, A.C.J.W., Gwinn, M., Bradley, L.A., Oostra, B.A., Van Duijn, C.M. and Khoury, M.J. (2008) A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. The American Journal of Human Genetics 82(3): 593-599. (Pubitemid 351726114)
27. Khan, R. (2011) Why genetic privacy could be doomed. Gene Expression, [online], http://blogs .discovermagazine.com/gnxp/2011/06/why-genetic-privacy- could-be-doomed/, accessed 9 June 2011.
28. Khoury, M.J. et al (2009) The scientific foundation for personal genomics: Recommendations from a national institutes of health-centers for disease control and prevention multidisciplinary workshop. Genetics in Medicine 11(8): 559-567.
29. Kutz, G. (2006) Nutrigenetic Testing: Tests Purchased from Four Web Sites Mislead Consumers. Washington DC: United States Government Accountability Office.
30. Kutz, G. (2010) Direct-to-Consumer Genetic Tests: Misleading Test Results are Further Complicated by Deceptive Marketing and Other Questionable Practices. Washington DC: United States Government Accountability Office.
31. Lezaun, J. (2006) Creating a new object of government. Social Studies of Science 36(4): 499-531.
32. Lippi, G., Favaloro, E.J. and Plebani, M. (2011) Direct-to-consumer testing: More risks than opportunities. International Journal of Clinical Practice 65(12): 1221-1229.
33. Liu, S. and Song, Y. (2010) Building genetic scores to predict risk of complex diseases in humans: Is it possible? Diabetes 59(11): 2729-2731.
34. Loconto, A. and Busch, L. (2010) Standards, techno-economic networks, and playing fields: Performing the global market economy. Review of International Political Economy 17(3): 507-536.
35. Lynch, S.N. (2008) Should genetic tests be regulated?, http://www.time.com/time/health/article/0,8599, 1825539,00.html, accessed 7 June 2011.
36. McCarthy, M.I. et al (2008) Genome-wide association studies for complex traits: Consensus, uncertainty and challenges. Nat Rev Genet 9(5): 356-369. (Pubitemid 351556063)
37. McGoey, L. (2012) Strategic unknowns: Towards a sociology of ignorance. Economy and Society 41(1): 1-16.
38. McGowan, M.L., Fishman, J.R. and Lambrixa, M. (2010) Personal genomics and individual identities: Motivations and moral imperatives of early users. New Genetics and Society 29(3): 261-290.
39. McGuire, A.L. and Burke, W. (2008) An unwelcome side effect of direct-to-consumer personal genome testing. JAMA: The Journal of the American Medical Association 300(22): 2669-2671.
40. McGuire, A.L., Diaz, C.M.,Wang, T. and Hilsenbeck, S.G. (2009) Social networkers' attitudes toward directto- consumer personal genome testing. American Journal of Bioethics 9(6-7): 3-10.
41. Mesko, B. (2009) Pathway genomics: Interview. ScienceRoll, [online], http://scienceroll.com/2009/11/30/ pathway-genomics-interview/, accessed 16 June 2011.
42. Michaels, D. (2008) Manufactured uncertainty. In: R. Proctor and L.L. Schiebinger (eds.) Agnotology: The Making and Unmaking of Ignorance. Stanford, CA: Stanford University Press, pp. 90-107.
43. Moreira, T. and Palladino, P. (2005) Between truth and hope: On parkinson's disease, neurotransplantation and the production of the 'self'. History of the Human Sciences 18(3): 55-82. (Pubitemid 43497509)
44. Mountain, J. (2008) 23andKids: Growing up genotyped. The Spittoon, [online], http://spittoon.23andme. com/2008/10/28/23andkids-growing-up- genotyped/, accessed 1 July 2011.
45. Offit, K. (2008) Genomic profiles for disease risk. JAMA: The Journal of the American Medical Association 299(11): 1353-1355.
46. Paynter, N.P. et al (2010) Association between a literature-based genetic risk score and cardiovascular events in women. JAMA: The Journal of the American Medical Association 303(7): 631-637.
47. Porter, T.M. (1995) Trust in Numbers: The Pursuit of Objectivity in Science and Public Life. Princeton, NJ: Princeton University Press.
48. Rashba, E. and Gamota, D. (2003) Anticipatory standards and the commercialization of nanotechnology. Journal of Nanoparticle Research 5(3): 401-407.
49. Ray, T. (2010) Navigenics agrees not to market genetic testing services directly to NY residents. Genome- Web, [online], http://www.genomeweb.com/dxpgx/ navigenics-agrees-not-market-genetic-testing-servicesdirectly- ny-residents, accessed 10 September 2011.
50. Reid, R.J. et al (2012) Association between health-service use and multiplex genetic testing. Genetics in Medicine 14(10): 852-859.
51. Richards, M. (2010) Reading the runes of my genome: A personal exploration of retail genetics. New Genetics and Society 29(3): 291-310.
52. Secretary's Advisory Committee On Genetics, Health And Society (SACGHS). (2008) U.S. System of Oversight of Genetic Testing: A Response to the Charge of the Secretary of Health and Human Services. Bethesda, MD: Department of Health and Human Services.
53. Secretary's Advisory Committee On Genetics, Health And Society (SACGHS). (2010) Direct-to-Consumer Genetic Testing. Bethesda, MD: Department of Health and Human Services.
54. Singer, E. (2008) Q&A: Linda Avey and Anne Wojcicki. Technology Review 111(6): 40.
55. Tamir, S. (2010) Direct-to-consumer genetic testing: Ethical-legal perspectives and practical considerations. Medical Law Review 18(2): 213-238.
56. Tomasson, M. (2009) Legal, ethical, and conceptual bottlenecks to the development of useful genomic tests. Annals of Health Law 18(2): 231-260.
57. Umbehr, J. (2008) An Interview with Navigenics, http://medgadget.com/ 2008/07/an-interview-with- navigenics-1.html, accessed 10 July 2011.
58. Vanier, V. (2010) Written Testimony of Vance Vanier, M.D., Chief Executive Officer Navigenics, Inc. [online], http://democrats.energycommerce. house.gov/documents/20100722/Vanier.Testimony.07.22.2010.pdf, accessed 20 June 2011.
59. Vorhaus, D. (2011) Closer scrutiny ahead for DTC genetic testing claims. Genomics Law Report, http:// www.genomicslawreport.com/index.php/2011/03/24/ closer-scrutiny-ahead-for-dtc-claims, accessed 16 June 2011.
60. Wadman, M. (2008) Gene-testing firms face legal battle. Nature 453(7199): 1148-1149. (Pubitemid 351913566)
61. Warburton, E. (2008) Navigenics - The Whole Interview, http://archive.blisstree.com/feel/navigenics-thewhole- interview/, accessed 14 June 2011.
62. Zuk, O., Hechter, E., Sunyaev, S.R. and Lander, E.S. (2012) The mystery of missing heritability: Genetic interactions create phantom heritability. Proceedings of the National Academy of Sciences 109(4): 1193-1198.